New Rhein Healthcare Investors
Selwyn Ho is an accomplished executive with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as Chief Executive Officer at Medigene AG since July 2022, Selwyn is focused on developing advanced TCR-guided therapies. In addition to this role, Selwyn holds several non-executive director positions at Antennova and Peptomyc, and serves as Executive In Residence at New Rhein Healthcare Investors. Previous leadership roles include Managing Director at Artemis Catalyst, where consulting services were provided to C-Suite executives, and EVP & Chief Business Officer at Connect Biopharma, overseeing a successful ~$220M IPO. With a solid educational background that includes a degree in Medicine from Imperial College London and various qualifications in pharmaceutical medicine and pain management, Selwyn Ho has a proven track record in corporate strategy, product commercialization, and market access.
This person is not in any teams
This person is not in any offices
New Rhein Healthcare Investors
New Rhein is a Venture Capital/ Private Equity investor. Its partners are former pharmaceutical industry executives having both operational and M&A experience. New Rhein invests in healthcare companies with the objective of helping management teams build their business into a profile strategic investors would find attractive. We use our knowledge of what strategic buyers want and our relationships to help our portfolio companies achieve this goal. Investment areas of focus include specialty Rx (eg hospital), branded and difficult to make Gx, OTC, biologics, vaccines, and emerging markets (in particular China and Brazil). We are interested in product only deals, carve-outs and entire company purchases.